Daniel P O'Malley

US Patent:

20220289736, Sep 15, 2022

Filed:

May 6, 2021

Appl. No.:

17/313319

Inventors:

- Princeton NJ, US
Shomir Ghosh - Brookline MA, US
William R. Roush - Tequesta FL, US
Edward James Olhava - Newton MA, US
Daniel O'Malley - New Hope PA, US

International Classification:

C07D 471/04
A61P 35/00
A61P 37/00
A61K 31/4745
A61K 31/5377
A61K 45/06

Abstract:

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity (e.g., a condition, disease or disorder associated with an insufficient immune response) that contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

US Patent:

20200157096, May 21, 2020

Filed:

Nov 25, 2019

Appl. No.:

16/693420

Inventors:

- Princeton NJ, US
Shomir Ghosh - Brookline MA, US
William R. Roush - Jupiter FL, US
Edward James Olhava - Newton MA, US
Daniel O'Malley - New Hope PA, US

International Classification:

C07D 471/04
A61P 35/00
A61P 37/00
A61K 31/4745
A61K 31/5377
A61K 45/06

Abstract:

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity (e.g., a condition, disease or disorder associated with an insufficient immune response) that contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

US Patent:

20190055236, Feb 21, 2019

Filed:

Feb 16, 2018

Appl. No.:

15/898258

Inventors:

- Princeton NJ, US
Shomir Ghosh - Brookline MA, US
William R. Roush - Jupiter FL, US
Edward James Olhava - Newton MA, US
Daniel O'Malley - New Hope PA, US

International Classification:

C07D 471/04
A61K 45/06
A61K 31/4745
A61K 31/5377
A61P 35/00

Abstract:

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity (e.g., a condition, disease or disorder associated with an insufficient immune response) that contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.